about
Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trialA phase 3 trial of RTS,S/AS01 malaria vaccine in African infantsSafety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trialImmunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialA 10 year study of the cause of death in children under 15 years in Manhiça, Mozambique.Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children.Assessment of coverage of preventive treatment and insecticide-treated mosquito nets in pregnant women attending antenatal care services in 11 districts in Mozambique in 2011: the critical role of supply chainAntimicrobial drug resistance trends of bacteremia isolates in a rural hospital in southern MozambiquePrevalence and risk factors of sexually transmitted infections and cervical neoplasia in women from a rural area of southern Mozambique.Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine.Prescription practices for malaria in Mozambique: poor adherence to the national protocols for malaria treatment in 22 public health facilities.Antimicrobial susceptibility and mechanisms of resistance in Shigella and Salmonella isolates from children under five years of age with diarrhea in rural Mozambique.RTS,S vaccination is associated with serologic evidence of decreased exposure to Plasmodium falciparum liver- and blood-stage parasites.Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigensRadiological findings in young children investigated for tuberculosis in Mozambique.Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial.Assessment of exposure to DDT and metabolites after indoor residual spraying through the analysis of thatch material from rural African dwellingsVarying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications.High Rates of Non-Tuberculous Mycobacteria Isolation in Mozambican Children with Presumptive Tuberculosis.Malaria in rural Mozambique. Part I: children attending the outpatient clinicMalaria in rural Mozambique. Part II: children admitted to hospital.Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria VaccineCause-specific mortality rates in sub-Saharan Africa and Bangladesh.Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique.Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.Rapid spread and genetic diversification of HIV type 1 subtype C in a rural area of southern Mozambique.Distinct TH1 and TH2 cellular responses associated with malaria protection and risk in RTS,S/AS01E vaccinees.A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.Improvement of fungal disease identification and management: combined health systems and public health approaches.Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria at sentinel sites in Mozambique, 2015.Invasive non-typhoidal Salmonella in Mozambican children.Epidemiology and clinical presentation of shigellosis in children less than five years of age in rural Mozambique.Adherence to Childhood Tuberculosis Treatment in Mozambique.Incidence of Tuberculosis Among Young Children in Rural Mozambique.Caretakers' perspectives of paediatric TB and implications for care-seeking behaviours in Southern Mozambique.Mozambique field epidemiology and laboratory training program: a pathway for strengthening human resources in applied epidemiology.Correction: Radiological Findings in Young Children Investigated for Tuberculosis in Mozambique.Correction: High Rates of Non-Tuberculous Mycobacteria Isolation in Mozambican Children with Presumptive Tuberculosis
P50
Q28254031-CC8A1387-AD28-4DD5-857A-998EB3F88B12Q28278852-5C0BDA31-9DEB-48C3-82B8-334EDE70BF1EQ28748565-8E5EABC9-F492-43A6-80C6-383224FF0C21Q30991737-EC6F16EB-2509-4DE7-A398-429C24009CA0Q33411580-19482BC2-9178-4503-A0F7-57A30B6CF8BBQ33430011-89B7227A-01AF-4C4B-824B-0B330869CD5CQ33430011-C4CF44E5-403E-42E1-ADF6-BBB8C7C864CCQ33730782-69231731-9E45-4D45-91B5-1100DFFBC35DQ34030297-10D29966-9CC9-4032-B794-43106E5AD56DQ34035360-2C1D9A98-C5A2-4112-941F-1C54F696A408Q34359432-5E082A25-E6D5-4CE6-BAF1-65E7A4185F14Q34487139-A468D247-B812-4442-A63E-DE13FC37215DQ34503789-9BB7D2B4-D2E2-497E-BFB5-1DE120C4A0C6Q34605990-3C1568A7-4C49-4075-8F52-418CFD247354Q35148353-3229E2FA-224B-400A-A137-E1E51DE276E7Q35330733-D4274012-DFBB-4C45-809C-6E131159C257Q35644712-82B280E9-F4F9-4411-80A0-FA5CE9DE84D7Q35742175-81AE45A3-1401-49B9-BD3F-E630D09CC6ABQ35769831-712E65D2-180B-4981-B874-751A443ABA14Q36178132-3782D0BA-F999-48A3-9EF6-1DA81439E236Q36251223-E7A524AF-DA41-47F7-8659-FDB0B57AD654Q36498863-4B06F05B-A207-429E-930E-26F5E355E7ABQ36509574-42ED8DE2-C1F0-4134-A294-4DF056D22B8EQ36603519-DB8CEC2E-260E-470D-AFF6-154A337448A9Q37063330-E0C87049-9ECB-465F-A201-C33295B46C1BQ37355917-AD013E17-E461-42DD-80D6-3F5D929F35B1Q38380487-731495F8-FEC4-4F85-9C87-894EE1FF0801Q38410749-899C7E8E-058B-4E8D-9D7B-32C1E0D7C63BQ38410749-D0199072-2B8A-410F-91B2-2664BD55B43AQ39157020-4E57361B-4251-484A-B4E5-B6E3D6F4D33FQ39262417-9171EE17-A678-4CA3-B979-45FCFE503D82Q39507890-411E33D8-4B48-4520-AD89-933F04838265Q40095617-64BE167A-6A51-4E04-88E5-2A4612F1ACABQ40266358-2F289737-A9CA-49EB-8233-A72F94AA83F5Q40378524-7F9F4C1A-DA63-475C-8BE9-0404E1B5200FQ40378524-AB0E29C6-C3AD-4CF5-8839-39A44E3831EFQ40435116-9A1A6E00-6B67-4380-9022-A51A7BA887E5Q40623794-8CE75258-6521-4251-992A-27A407139244Q40840565-0A684129-E8C6-4390-A15E-CF82E1430496Q41074217-C53C3165-A776-42EA-82BF-A0F5D9D87F73
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jahit Sacarlal
@ast
Jahit Sacarlal
@en
Jahit Sacarlal
@es
Jahit Sacarlal
@nl
Jahit Sacarlal
@sl
type
label
Jahit Sacarlal
@ast
Jahit Sacarlal
@en
Jahit Sacarlal
@es
Jahit Sacarlal
@nl
Jahit Sacarlal
@sl
prefLabel
Jahit Sacarlal
@ast
Jahit Sacarlal
@en
Jahit Sacarlal
@es
Jahit Sacarlal
@nl
Jahit Sacarlal
@sl
P1053
R-3172-2016
P106
P1153
9845325600
P31
P496
0000-0003-1059-217X